N/A
Manufactured by Merz Pharmaceuticals, LLC
19,591 FDA adverse event reports analyzed
Last updated: 2026-04-15
GLYCOPYRROLATE is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Merz Pharmaceuticals, LLC. The most commonly reported adverse reactions for GLYCOPYRROLATE include DYSPNOEA, ASTHMA, WHEEZING, COUGH, PNEUMONIA. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for GLYCOPYRROLATE.
Out of 5,223 classified reports for GLYCOPYRROLATE:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 19,591 FDA FAERS reports that mention GLYCOPYRROLATE. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include DYSPNOEA, ASTHMA, WHEEZING, COUGH, PNEUMONIA, DRUG INEFFECTIVE. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list Merz Pharmaceuticals, LLC in connection with GLYCOPYRROLATE. Always verify the specific product and NDC with your pharmacist.